Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q1 2024 · 10-Q
Revenue$138.50M$138.50M+13.4% vs Q1 2023 Net Income-$38.76M-$38.76MN/M vs Q1 2023 EPS Diluted-$0.36-$0.36N/M vs Q1 2023 Gross Profit$104,814,000+13.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$31,574,000N/M Free Cash Flowderived-$43,358,000N/M Margins · derivedGross margin75.7%−0.1 pt vs Q1 2023
Operating margin-30.0%+19.3 pt vs Q1 2023
Net margin-28.0%+15.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 2, 2024 · 32 d after period end